G1 Therapeutics, Inc.
NASDAQ:GTHX
7.16 (USD) • At close September 17, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 82.511 | 51.301 | 31.476 | 45.285 | 0 | 0 | 0 | 0 | 0.522 | 1.043 |
| Cost of Revenue
| 7.195 | 3.748 | 2.016 | 0 | 0.356 | 0.175 | 0.089 | 0.067 | 12.73 | 5.019 |
| Gross Profit
| 75.316 | 47.553 | 29.46 | 45.285 | -0.356 | -0.175 | -0.089 | -0.067 | -12.208 | -3.976 |
| Gross Profit Ratio
| 0.913 | 0.927 | 0.936 | 1 | 0 | 0 | 0 | 0 | -23.387 | -3.814 |
| Reseach & Development Expenses
| 43.711 | 83.316 | 76.225 | 73.271 | 89.002 | 70.683 | 53.881 | 25.161 | 12.73 | 5.019 |
| General & Administrative Expenses
| 0 | 0 | 0 | 68.49 | 40.039 | 18.603 | 7.087 | 5.23 | 3.216 | 2.702 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 71.132 | 100.415 | 95.692 | 68.49 | 40.039 | 18.603 | 7.087 | 5.23 | 3.216 | 2.702 |
| Other Expenses
| 2.24 | 0.003 | -0.346 | -0.542 | 6.594 | 3.998 | 0.888 | 0.182 | 0.018 | 0 |
| Operating Expenses
| 114.843 | 183.731 | 171.917 | 141.761 | 129.041 | 89.286 | 60.968 | 30.391 | 15.946 | 2.701 |
| Operating Income
| -39.527 | -136.178 | -142.457 | -96.476 | -129.041 | -89.286 | -60.968 | -30.391 | -15.424 | -6.678 |
| Operating Income Ratio
| -0.479 | -2.654 | -4.526 | -2.13 | 0 | 0 | 0 | 0 | -29.548 | -6.405 |
| Total Other Income Expenses Net
| -5.325 | -9.681 | -4.97 | -1.368 | 6.594 | 3.998 | 0.847 | 0.1 | -4.839 | -0 |
| Income Before Tax
| -44.852 | -145.859 | -147.427 | -97.844 | -122.447 | -85.288 | -60.121 | -30.291 | -20.263 | -6.678 |
| Income Before Tax Ratio
| -0.544 | -2.843 | -4.684 | -2.161 | 0 | 0 | 0 | 0 | -38.818 | -6.405 |
| Income Tax Expense
| 3.115 | 1.7 | 0.925 | 1.41 | -0.356 | 3.998 | 0.041 | 0.082 | 4.857 | 0.502 |
| Net Income
| -47.967 | -147.559 | -148.352 | -99.254 | -122.091 | -85.288 | -60.121 | -30.291 | -20.263 | -7.181 |
| Net Income Ratio
| -0.581 | -2.876 | -4.713 | -2.192 | 0 | 0 | 0 | 0 | -38.818 | -6.886 |
| EPS
| -0.93 | -3.38 | -3.54 | -2.62 | -3.26 | -2.56 | -3.3 | -1.48 | -0.99 | -5.85 |
| EPS Diluted
| -0.93 | -3.38 | -3.54 | -2.62 | -3.26 | -2.56 | -3.3 | -1.48 | -0.99 | -5.85 |
| EBITDA
| -39.014 | -134.897 | -142.76 | -96.066 | -129.041 | -89.286 | -60.838 | -30.241 | -10.525 | -6.661 |
| EBITDA Ratio
| -0.473 | -2.63 | -4.536 | -2.121 | 0 | 0 | 0 | 0 | -20.163 | -6.388 |